Rituximab in patients with primary CNS lymphoma (HOVON 105/ALLG NHL 24): a randomised, open-label, phase 3 intergroup study

Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)

Michael Pfreundschuh, Jöerg Schubert, Marita Ziepert et al. · The Lancet Oncology · 2008 · 1.1K citations

Medicine, Immunology, Oncology +7

Report of an International Workshop to Standardize Baseline Evaluation and Response Criteria for Primary CNS Lymphoma

Lauren E. Abrey, Tracy T. Batchelor, Andrés J.M. Ferreri et al. · Journal of Clinical Oncology · 2005 · 906 citations

Medicine, Neurology, Oncology +17

High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial

Andrés JM Ferreri, Michele Reni, Marco Foppoli et al. · The Lancet · 2009 · 662 citations · Full text

Medicine, Oncology, Pharmacology +10

High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial

Eckhard Thiel, Agnieszka Korfel, Peter Martus et al. · The Lancet Oncology · 2010 · 622 citations

Medicine, Oncology, Pharmacotherapy +10

Primary Central Nervous System Lymphoma: The Memorial Sloan-Kettering Cancer Center Prognostic Model

Lauren E. Abrey, Leah Ben‐Porat, Katherine S. Panageas et al. · Journal of Clinical Oncology · 2006 · 620 citations

Medicine, Oncology, Hematologic Oncology +13